RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Use of Dalteparin beyond 6 Months in Cancer Patients with VTE is Feasible
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 13
SP 13
OP 14
DO 10.1177/155989771313006
UL http://mdc.sagepub.com/content/13/13/13.abstract
AB Although the guidelines for treating venous thromboembolism (VTE) in cancer patients recommend anticoagulation with low-molecular-weight heparin for at least 3 to 6 months, or for the duration of the malignancy, uncertainty exists concerning whether to extend anticoagulation longer to prevent recurrence of VTE. The objective of the Evaluation of Dalteparin for Long-Term (One Year) Treatment of Blood Clots in Subjects With Cancer study [DALTECAN; NCT00942968] was to assess the consequences of extending anticoagulation with dalteparin beyond 6 months in cancer-associated VTE.